Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation

New England Journal of Medicine

Volumn 370, Issue 19, 2014, Pages 1781-1789

  Chemaly, Roy F ^a   Ullmann, Andrew J ^b   Stoelben, Susanne ^d   Richard, Marie Paule ^d   Bornhaüser, Martin ^e   Groth, Christoph ^f   Einsele, Hermann ^g   Silverman, Margarida ^h   Mullane, Kathleen M ⁱ   Brown, Janice ^j   Nowak, Horst ^c   Kol̈ling, Katrin ^d   Stobernack, Hans P ^d   Lischka, Peter ^d   Zimmermann, Holger ^d   Rub̈samen Schaeff, Helga ^d   Champlin, Richard E ^a   Ehninger, Gerhard ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University Medical Center   (Germany)

^c Private Statistical Consultant   (Germany)

^d AiCuris GmbH   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h UNIVERSITY OF IOWA   (United States)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j STANFORD UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; LETERMOVIR; PLACEBO;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL ACTIVITY; ARTICLE; BENIGN TUMOR; CAUSE OF DEATH; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DNA DETERMINATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EYE DISEASE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFECTION; KIDNEY DISEASE; LYMPHATIC SYSTEM INFECTION; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYELOID LEUKEMIA; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; NUTRITIONAL DISORDER; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SKIN DISEASE; THORAX DISEASE; TREATMENT DURATION; TREATMENT FAILURE; UROGENITAL TRACT DISEASE; VOMITING;

ACETATES; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; KAPLAN-MEIER ESTIMATE; OPPORTUNISTIC INFECTIONS; QUINAZOLINES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 84899819902     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1309533     Document Type: Article

References (18)

1. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010;24:319-37.
2. Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program 2011;2011:305-9.
3. Sampathkumar P, Paya C. Pathogenesis in transplant recipients. In: Emery V, ed. Human cytomegalovirus. London: International Medical Press, 2007:7.1-7.14.
4. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006;71:154-63. (Pubitemid 44223768)
5. Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010;54:1290-7.
6. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011;85:10884-93.
7. Marschall M, Stamminger T, Urban A, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother 2012;56:1135-7.
8. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011;11:1079-84.
9. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7. (Pubitemid 34289682)
10. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008;111:5403-10.
11. Boeckh M, Bowden RA, Storer B, et al. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:343-51. (Pubitemid 32677436)
12. Ghaffari SH, Obeidi N, Dehghan M, Alimoghaddam K, Gharehbaghian A, Ghavamzadeh A. Monitoring of cytomegalovirus reactivation in bone marrow transplant recipients by real-time PCR. Pathol Oncol Res 2008;14:399-409.
13. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11:284-92. [Erratum, Lancet Infect Dis 2011;11:343.]
14. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013;369:1227-36.
15. Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC. Randomized comparison of oral valacy-clovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003;36:749-58. (Pubitemid 36337979)
16. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med 1993;118:179-84. (Pubitemid 23034802)
17. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-8. (Pubitemid 23034801)
18. Stoelben S, Arns W, Renders L, et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int 2014;27:77-86.